From a biologic perspective, this finding supports the notion that the poor outcome of tumours with BRAF mutation is shared with some non-BRAF-mutated tumours, suggesting that they have common biology driving poor survival after relapse [127]. This evidence concerns the gene BRAF and neoplasm.